Clinical Trial Update: A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment [Phase 3]

View source ↗

Summary

Phase 3 study evaluating peg-tibatinase versus placebo for classical homocystinuria due to CBS deficiency; the trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homocystinuria

Drugs mentioned

• Pegtibatinase (pegtibatinase)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Homocystinuria | Phase 3 | Status: ACTIVE_NOT_RECRUITING